'''د کوویډ-۱۹ فایزر – بیو اېن‌ټېک واکسین''' چې غیر اختصاصي نړیوال نوم یې '''توزینامران''' (tozinameran) دی او د '''کمیرنېټي''' (Comirnaty) په سوداګریز نامه پلورل کېږي، د کوویډ-۱۹ ناروغۍ لپاره یو mRNA واکسین دی چې د بیوټکنالوژۍ جرمني شرکت بیو اېن‌ټېک (BioNTech) جوړ کړی دی. بیو اېن‌ټېک شرکت د دغه واکسین د پراختیا لپاره په کلینیکي ازمېښتونو، تدارکاتو او تولید کې له امریکايي شرکت فایزر (Pfizer) سره ګډ کار وکړ. د دغه واکسین استفاده په ځینو هېوادونو کې له پنځو کلونو پورته اشخاصو ته، په ځینو هېوادونو کې له دوولس کلونو پورته اشخاصو ته او په ځینو هېوادونو کې هم تر شپاړس کلونو پورته اشخاصو ته مجاز ده تر څو د کوویډ-۱۹ په مقابل کې خوندي شي چې د SARS-CoV-2 ویروس له سرایت څخه را پیدا کېږي. دا واکسین د عضلاتو له لارې تزریق کېږي. د نوکلیوزیډ په مرسته له اصلاح شوي mRNA څخه جوړ دي چې د SARS-CoV-2 ویروس د بشپړ سپایک پروتین بدله شوې بڼه کود کوي. لومړنۍ سپارښتنې ښیي چې دا واکسیناسیون دوو ډوزونو ته اړتیا لري چې په خپلو کې د ۲۱ ورځو په واټن تزریق کېږي، خو وروسته دا واټن په متحدو ایالتونو کې تر ۴۲ ورځو او په کاناډا کې تر څلورو میاشتو پورې ډېر شو.<ref name="Comirnaty EPAR">{{cite web|title=Comirnaty EPAR|url=https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty|access-date=24 October 2021|website=[[European Medicines Agency]] (EMA)|archive-url=https://web.archive.org/web/20211218220137/https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty|archive-date=19 December 2021}}</ref><ref name="FDA PR 20210823">{{Cite press release|title=FDA Approves First COVID-19 Vaccine|date=23 August 2021|publisher=U.S. [[Food and Drug Administration]] (FDA)|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine|access-date=23 August 2021|archive-url=https://web.archive.org/web/20210823143040/https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine|archive-date=23 August 2021|url-status=live}}</ref><ref>{{cite news|date=11 November 2020|title=What you need to know about BioNTech – the European company behind Pfizer's Covid-19 vaccine|publisher=CNBC|url=https://www.cnbc.com/2020/11/11/biontech-the-european-company-behind-pfizers-covid-19-vaccine.html|access-date=14 January 2021|vauthors=Browne R|archive-date=4 March 2021|archive-url=https://web.archive.org/web/20210304192058/https://www.cnbc.com/2020/11/11/biontech-the-european-company-behind-pfizers-covid-19-vaccine.html|url-status=live}}</ref><ref name="nytimes-2020-11-09">{{cite news|title=Pfizer's early data shows vaccine is more than 90% effective|vauthors=Thomas K, Gelles D, Zimmer C|work=The New York Times|url=https://www.nytimes.com/2020/11/09/health/covid-vaccine-pfizer.html|date=9 November 2020|access-date=9 November 2020|archive-date=23 November 2020|archive-url=https://web.archive.org/web/20201123032409/https://www.nytimes.com/2020/11/09/health/covid-vaccine-pfizer.html|url-status=live}}</ref><ref name="CDC PR 20211102">{{cite press release|title=CDC Recommends Pediatric COVID-19 Vaccine for Children 5 to 11 Years|website=U.S. [[Centers for Disease Control and Prevention]] (CDC)|date=2 November 2021|url=https://www.cdc.gov/media/releases/2021/s1102-PediatricCOVID-19Vaccine.html|access-date=4 November 2021}}</ref><ref name="CA Regulatory Decision Summary">{{cite web|title=Regulatory Decision Summary - Pfizer-BioNTech COVID-19 Vaccine|publisher=[[Health Canada]]|url=https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00802|access-date=11 May 2021|archive-date=12 May 2021|archive-url=https://web.archive.org/web/20210512081946/https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00802|url-status=live}}</ref><ref>{{cite press release|title=First COVID-19 vaccine approved for children aged 12 to 15 in EU|website=[[European Medicines Agency]] (EMA)|date=28 May 2021|url=https://www.ema.europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12-15-eu|access-date=29 May 2021|archive-date=28 May 2021|archive-url=https://web.archive.org/web/20210528212329/https://www.ema.europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12-15-eu|url-status=live}}</ref><ref>{{cite web|title=Information for UK recipients on Pfizer/BioNTech COVID-19 vaccine|publisher=[[Medicines and Healthcare products Regulatory Agency]] (MHRA)|date=8 December 2020|url=https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/information-for-uk-recipients-on-pfizerbiontech-covid-19-vaccine|access-date=29 May 2021|archive-date=30 May 2021|archive-url=https://web.archive.org/web/20210530190316/https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/information-for-uk-recipients-on-pfizerbiontech-covid-19-vaccine|url-status=live}}</ref><ref name="pmid33053279">{{cite journal|vauthors=Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, Şahin U, Gruber WC|display-authors=6|title=Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates|journal=[[The New England Journal of Medicine]]|date=October 2020|volume=383|issue=25|pages=2439–50|pmid=33053279|pmc=7583697|doi=10.1056/NEJMoa2027906|doi-access=free|title-link=doi}}</ref><ref name="NCT04368728">{{cite journal|title=Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals|website=ClinicalTrials.gov|date=30 April 2020|url=https://clinicaltrials.gov/ct2/show/NCT04368728|access-date=5 August 2021|archive-date=11 October 2020|archive-url=https://web.archive.org/web/20201011084828/https://clinicaltrials.gov/ct2/show/NCT04368728/|url-status=live}}</ref><ref name="palca">{{cite news|vauthors=Palca J|title=Pfizer says experimental COVID-19 vaccine is more than 90% effective|newspaper=NPR.org|url=https://www.npr.org/sections/health-shots/2020/11/09/933006651/pfizer-says-experimental-covid-19-vaccine-is-more-than-90-effective|publisher=NPR|date=9 November 2020|access-date=9 November 2020|archive-date=9 November 2020|archive-url=https://web.archive.org/web/20201109130110/https://www.npr.org/sections/health-shots/2020/11/09/933006651/pfizer-says-experimental-covid-19-vaccine-is-more-than-90-effective|url-status=live}}</ref><ref name="herper">{{cite web|vauthors=Herper M|title=Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate|url=https://www.statnews.com/2020/11/09/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate/|work=[[Stat (website)|Stat News]]|access-date=9 November 2020|date=9 November 2020|archive-date=9 November 2020|archive-url=https://web.archive.org/web/20201109114554/https://www.statnews.com/2020/11/09/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate/|url-status=live}}</ref><ref>{{cite news|title=Canada vaccine panel recommends 4 months between COVID doses|website=ABC News|date=4 March 2021|url=https://abcnews.go.com/International/wireStory/canada-vaccine-panel-recommends-months-covid-doses-76239947|access-date=9 July 2021|archive-date=26 July 2021|archive-url=https://web.archive.org/web/20210726011545/https://abcnews.go.com/International/wireStory/canada-vaccine-panel-recommends-months-covid-doses-76239947|url-status=live}}</ref><ref>{{cite report|author=Public Health Agency of Canada|title=Recommendations on the use of COVID-19 vaccines|website=Health Canada|date=2 July 2021|url=https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/recommendations-use-covid-19-vaccines-en.pdf|access-date=9 July 2021|archive-date=23 June 2021|archive-url=https://web.archive.org/web/20210623231743/https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/recommendations-use-covid-19-vaccines-en.pdf|url-status=live}}</ref><ref>{{Cite web|vauthors=Ellis R|title=CDC: Gap Between Vaccine Doses Could Be 6 Weeks|url=https://www.webmd.com/vaccines/covid-19-vaccine/news/20210122/cdc-gap-between-vaccine-doses-could-be-6-weeks|access-date=8 July 2021|website=WebMD|archive-date=4 May 2021|archive-url=https://web.archive.org/web/20210504162757/https://www.webmd.com/vaccines/covid-19-vaccine/news/20210122/cdc-gap-between-vaccine-doses-could-be-6-weeks|url-status=live}}</ref>

کلینیکي ازمېښتونه یې د ۲۰۲۰ ز کال په اپرېل میاشت کې پیل شول. د ۲۰۲۰ ز کال تر نومبر میاشت پورې واکسین د کلینکي ازمېښتونو درېیم پړاو ته دننه شو او څه باندې ۴۰۰۰۰ کسانو برخه په کې واخیسته. د ډېټا د څېړنې یوه لنډمهالي تحلیل وښوده چې دغه واکسین تر دویم ډوز اووه ورځې وروسته د عفونت یا سرایت په مخنیوي کې ۹۱.۳ سلنه بالقوه اغېز درلود او هېڅ کومه جدي روغتیايي اندېښنه هم ورسره نه وه. ډېری جانبي عوارض یې خفیف یا متوسط دي او د څو ورځو په جریان کې له منځه ځي. تر ټولو معمول یې د تزریق په ځای کې یو خفیف درد، ستړیا او د سر درد دي. د حساسیت په څېر لوی جانبي عوارض يې ډېر کم پېښ شوي او د هېڅ اوږدمهالې ستونزې راپور هم نه دی ورکړل شوی. <ref name="NCT043687282">{{cite journal|title=Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals|website=ClinicalTrials.gov|date=30 April 2020|url=https://clinicaltrials.gov/ct2/show/NCT04368728|access-date=5 August 2021|archive-date=11 October 2020|archive-url=https://web.archive.org/web/20201011084828/https://clinicaltrials.gov/ct2/show/NCT04368728/|url-status=live}}</ref><ref name="BioNTechUpdate">{{cite press release|title=Update on our COVID-19 vaccine development program with BNT162b2|url=https://investors.biontech.de/static-files/53f0968a-279b-4f82-a2fc-d67dcb6e4e91|format=PDF|publisher=[[BioNTech]]|date=2 December 2020|access-date=12 December 2020|archive-date=3 December 2020|archive-url=https://web.archive.org/web/20201203004920/https://investors.biontech.de/static-files/53f0968a-279b-4f82-a2fc-d67dcb6e4e91|url-status=live}}</ref><ref name="herper2">{{cite web|vauthors=Herper M|title=Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate|url=https://www.statnews.com/2020/11/09/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate/|work=[[Stat (website)|Stat News]]|access-date=9 November 2020|date=9 November 2020|archive-date=9 November 2020|archive-url=https://web.archive.org/web/20201109114554/https://www.statnews.com/2020/11/09/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate/|url-status=live}}</ref><ref name=":4">{{cite press release|title=Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study|website=BioNTech|date=1 April 2021|url=https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-confirm-high-efficacy-and-no-serious-safety|access-date=11 April 2021|archive-date=4 April 2021|archive-url=https://web.archive.org/web/20210404130905/https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-confirm-high-efficacy-and-no-serious-safety|url-status=live}}</ref><ref name=":7">{{Cite web|date=19 November 2021|title=Pfizer-BioNTech COVID-19 Vaccine (also known as Comirnaty) Overview and Safety|url=https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html|archive-url=https://web.archive.org/web/20211206135118/https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html|archive-date=6 December 2021|access-date=27 September 2021|website=U.S. [[Centers for Disease Control and Prevention]] (CDC)|url-status=live}}</ref><ref name="pmid33301246">{{cite journal|vauthors=Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC|display-authors=6|title=Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine|journal=N Engl J Med|volume=383|issue=27|pages=2603–15|date=December 2020|pmid=33301246|pmc=7745181|doi=10.1056/NEJMoa2034577|doi-access=free|title-link=doi}}</ref><ref>{{cite web|title=Questions and Answers About Pfizer–BioNTech COVID-19 Vaccine|url=https://www.cvdvaccine-us.com/faqs|archive-url=https://web.archive.org/web/20201223131833/https://www.cvdvaccine-us.com/faqs|archive-date=23 December 2020|access-date=16 December 2020|publisher=Pfizer|url-status=live}}</ref><ref name="nhs-cvac">{{cite web|date=7 December 2020|title=Coronavirus vaccine|url=https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/|archive-url=https://web.archive.org/web/20201207150116/https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/|archive-date=7 December 2020|access-date=7 December 2020|publisher=National Health Service|url-status=live}}</ref>

دا واکسین د کوویډ-۱۹ لومړنی واکسین دی چې یوې دقیقې نظارتي مرجع يې د بیړنۍ استفادې اجازه صادره کړه او د منظمې استفادې لپاره هم لومړنی واکسین دی. د ۲۰۲۰ ز کال په ډسمبر میاشت کې بریتانیا لومړنی هېواد و چې په بیړنیو شرایطو کې یې د دغه واکسین استفادې ته اجازه ورکړه. دا واکسین په ډېرو هېوادونو کې د بېلابېلو کچو لپاره د کارولو اجازه لري. د ۲۰۲۱ ز کال د اګسټ میاشتې په ۲۳مه نېټه د کوویډ-۱۹ لومړنی واکسین شو چې د امریکا د خوړو او درملو د سازمان (FDA) له‌خوا تر شپاړس کلونو د پورته اشخاصو لپاره تایید شو.<ref name="ukgov12-22">{{cite press release|title=UK medicines regulator gives approval for first UK COVID-19 vaccine|url=https://www.gov.uk/government/news/uk-medicines-regulator-gives-approval-for-first-uk-covid-19-vaccine|publisher=[[Medicines and Healthcare products Regulatory Agency]] (MHRA)|access-date=2 December 2020|date=2 December 2020|archive-date=17 March 2021|archive-url=https://web.archive.org/web/20210317204122/https://www.gov.uk/government/news/uk-medicines-regulator-gives-approval-for-first-uk-covid-19-vaccine|url-status=live}}</ref><ref name="boseley2">{{cite news|date=2 December 2020|title=UK approves Pfizer/BioNTech Covid vaccine for rollout next week|work=[[The Guardian]]|url=https://www.theguardian.com/society/2020/dec/02/pfizer-biontech-covid-vaccine-wins-licence-for-use-in-the-uk|access-date=14 December 2020|archive-url=https://web.archive.org/web/20201202074938/https://www.theguardian.com/society/2020/dec/02/pfizer-biontech-covid-vaccine-wins-licence-for-use-in-the-uk|archive-date=2 December 2020|vauthors=Boseley S, Halliday J|url-status=live}}</ref><ref name="Swiss authorization">{{cite press release|title=Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland|url=https://www.bag.admin.ch/bag/en/home/das-bag/aktuell/medienmitteilungen.msg-id-81761.html|publisher=[[Swissmedic|Swiss Agency for Therapeutic Products (Swissmedic)]]|date=19 December 2020|access-date=19 December 2020|archive-date=10 January 2021|archive-url=https://web.archive.org/web/20210110142826/https://www.bag.admin.ch/bag/en/home/das-bag/aktuell/medienmitteilungen.msg-id-81761.html|url-status=live}}</ref><ref>{{Cite web|title=COVID-19 Vaccine Tracker: Pfizer/BioNTech: BNT162b2|url=https://covid19.trackvaccines.org/vaccines/6/|archive-url=https://web.archive.org/web/20210508175111/https://covid19.trackvaccines.org/vaccines/6/|archive-date=8 May 2021|access-date=8 May 2021|publisher=[[McGill University]]|url-status=live}}</ref><ref>{{cite web|date=3 February 2021|title=Pfizer–BioNTech COVID-19 Vaccine|url=https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine|archive-url=https://web.archive.org/web/20210114221304/https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-COVID-19/pfizer-biontech-COVID-19-vaccine|archive-date=14 January 2021|access-date=5 February 2021|publisher=U.S. [[Food and Drug Administration]] (FDA)|url-status=live}}</ref><ref>{{cite web|date=20 November 2020|title=F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away|url=https://www.nytimes.com/2020/12/11/health/pfizer-vaccine-authorized.html|archive-url=https://web.archive.org/web/20201212023020/https://www.nytimes.com/2020/12/11/health/pfizer-vaccine-authorized.html|archive-date=12 December 2020|website=[[The New York Times]]|vauthors=Thomas K|url-status=live}}</ref><ref>{{Cite web|author=Australian Government Department of Health|date=24 January 2021|title=About the Pfizer/BioNTech COVID-19 vaccine|url=https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/learn-about-covid-19-vaccines/about-the-pfizerbiontech-covid-19-vaccine|archive-url=https://web.archive.org/web/20210523030500/https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/learn-about-covid-19-vaccines/about-the-pfizerbiontech-covid-19-vaccine|archive-date=23 May 2021|access-date=31 May 2021|website=Australian Government Department of Health|url-status=live}}</ref><ref name="FDA Comirnaty">{{cite web|date=23 August 2021|title=Comirnaty|url=https://www.fda.gov/vaccines-blood-biologics/comirnaty|archive-url=https://web.archive.org/web/20211203134846/https://www.fda.gov/vaccines-blood-biologics/comirnaty|archive-date=3 December 2021|access-date=23 August 2021|website=U.S. [[Food and Drug Administration]] (FDA)|id=STN: 125742|url-status=live}}</ref><ref name="CNN 20210823">{{Cite news|vauthors=Howard J|date=23 August 2021|title=FDA grants full approval to Pfizer/BioNTech Covid-19 vaccine, opening door to more vaccine mandates|work=CNN|url=https://www.cnn.com/2021/08/23/health/fda-approval-pfizer-covid-vaccine/index.html|access-date=23 August 2021}}</ref>

د ۲۰۲۱ ز کال تر سپټمبر میاشت پورې د دغه شرکت له‌خوا د کوویډ-۱۹ څه باندې ۱.۵ میلیارد ډوزه واکسین نړۍ ته لېږل شوی دی. د ۲۰۲۱ ز کال د مارچ میاشتې له ۳۰مې نېټې را وروسته فایزر او بیو اېن‌ټېک شرکتونو غوښتل چې په ۲۰۲۱ ز کال کې شاوخوا ۲.۵ میلیارد ډوزه تولید کړي.وېش او زېرمه کول یې یو لوجېستيکي ګواښ دی، ځکه چې واکسین باید په ډېره ټيټه تودوخه کې ذخیره شي. بیو اېن‌ټېک او فایزر شرکتونه یې دا مهال د یوې داسې کنګل بڼې د ازمېښت په حال کې دي چې تر یخ په ښکته حالت کې ذخیرې ته اړتیا ونه‌لري.<ref>{{Cite web|date=22 September 2021|title=Pfizer and BioNTech expand collaboration with U.S. to provide 500 million additional COVID-19 vaccine doses at not-for-profit price for donation to poorest countries|url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-expand-collaboration-us-provide-500|archive-url=https://web.archive.org/web/20210922133111/https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-expand-collaboration-us-provide-500|archive-date=22 September 2021|url-status=live}}</ref><ref>{{cite press release|date=17 February 2021|title=Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of Comirnaty|publisher=BioNTech|url=https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-supply-european-union-200-million-additional|access-date=1 March 2021|archive-date=26 February 2021|archive-url=https://web.archive.org/web/20210226164309/https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-supply-european-union-200-million-additional|url-status=live}}</ref><ref name="Bloom2p5b">{{cite news|vauthors=Kresge N|title=BioNTech Raises Covid Vaccine Target to 2.5 Billion Doses|website=Bloomberg|date=30 March 2021|url=https://www.bloomberg.com/news/articles/2021-03-30/biontech-raises-2021-covid-vaccine-target-to-2-5-billion-doses|access-date=11 April 2021|archive-date=11 April 2021|archive-url=https://web.archive.org/web/20210411125303/https://www.bloomberg.com/news/articles/2021-03-30/biontech-raises-2021-covid-vaccine-target-to-2-5-billion-doses|url-status=live}}</ref><ref name="Rosales-2021">{{cite book|last1=Rosales-Mendoza|editor3-first=Omar|language=en|url=https://books.google.com/books?id=zcwnEAAAQBAJ&q=COVID-19+vaccine+elsevier|pages=129–152|isbn=978-0-323-90248-9|location=London|publisher=Academic Press|date=2021|title=Biomedical Innovations to Combat COVID-19|editor3-last=González-Ortega|first1=Sergio|editor2-first=Mauricio|editor2-last=Comas-García|editor1-first=Sergio|editor1-last=Rosales-Mendoza|first3=Maria|last3=de Lourdes.Betancourt-Mendiola|first2=Alejandro|last2=Wong-Arse|chapter=8. RNA based vaccines against SARS COV-2}}</ref><ref>{{cite news|vauthors=Hopkins JS|title=Pfizer to Test Covid-19 Vaccine That Doesn't Need Ultracold Storage|website=The Wall Street Journal|date=30 March 2021|url=https://www.wsj.com/articles/pfizer-to-test-covid-19-vaccine-that-doesnt-need-ultracold-storage-11617129345|access-date=16 May 2021|url-access=subscription|archive-date=15 May 2021|archive-url=https://web.archive.org/web/20210515053429/https://www.wsj.com/articles/pfizer-to-test-covid-19-vaccine-that-doesnt-need-ultracold-storage-11617129345|url-status=live}}</ref>

== طبي استفادې ==
د کوویډ-۱۹ فایزر-بیو اېن‌ټېک واکسین له SARS-CoV-2 ویروس څخه د راپیدا شوي کوویډ-۱۹ په مقابل کې د خوندیتوب لپاره کارول کېږي چې S انټيجن ته خوندي غبرګون رامنځته کوي. دا واکسین د کوویډ-۱۹ له امله د مړینو او عوارضو د راکمولو لپاره کارول کېږي.

دا واکسین په یوه داسې ګڼ‌ډوزه بوتلګي کې وړاندې کېږي چې بشپړ سپین دی، سټریل شوی دی او منجمد او ساتونکي مواد نه‌لري. تر ترزیق وړاندې باید د کوټې په تودوخه کې ګرم شي یعنې له کنګل حالت څخه وایستل شي.<ref name="FDA EUA Report">{{cite report|url=https://www.fda.gov/media/144416/download|format=PDF|title=Pfizer–BioNTech COVID-19 Vaccine Emergency Use Authorization Review Memorandum|website=U.S. [[Food and Drug Administration]] (FDA)|date=14 December 2020|access-date=14 December 2020|archive-date=29 January 2021|archive-url=https://web.archive.org/web/20210129152900/https://www.fda.gov/media/144416/download|url-status=live}} {{PD-notice}}</ref>

په لومړۍ دوره کې یې دوه ډوزونه دي. د روغتیا نړیوال سازمان (WHO) سپارښتنه کوي چې د ډوزونو تر منځ باید له درېیو تر څلورو اونیو واټن وي. که دویم ډوز تر دوولسمې اونۍ پورې وځنډول شي، په عمر خوړلیو کسانو کې د ټولو اندېښمنوونکو بڼو په مقابل کې خوندیتوب ډېروي. د پيچ څېړنیزه ډله په دې باور ده چې د ډلتا بڼې په مقابل کې مناسب واټن اته اونۍ دی، که واټنونه تر دې ډېر شي، ښايي واکسین اخیستونکي کسان زیان‌منونکي شي.<ref name="pitch-8weeks">{{cite news|title=Pfizer vaccine second dose has 'sweet spot' after eight weeks, UK scientists say|url=https://www.theguardian.com/world/2021/jul/23/pfizer-vaccine-second-dose-has-sweet-spot-after-eight-weeks-uk-scientists-say|archive-url=https://web.archive.org/web/20211118180256/https://www.theguardian.com/world/2021/jul/23/pfizer-vaccine-second-dose-has-sweet-spot-after-eight-weeks-uk-scientists-say|archive-date=18 November 2021|access-date=26 July 2021|date=23 July 2021|url-status=live}}</ref>

په ځینو هېوادونو کې کېدای شي درېیم او څلورم ډوز هم ور زیات شي.<ref name="FDA PR 20210812">{{cite press release|title=Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals|website=U.S. [[Food and Drug Administration]] (FDA)|date=12 August 2021|url=https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised|archive-url=https://web.archive.org/web/20211207181329/https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised|archive-date=7 December 2021|access-date=13 August 2021|url-status=live}}</ref><ref name="CDC immunocompromised">{{cite web|title=COVID-19 Vaccines for Moderately or Severely Immunocompromised People|website=U.S. [[Centers for Disease Control and Prevention]] (CDC)|date=13 August 2021|url=https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html|archive-url=https://web.archive.org/web/20211210092203/https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html|archive-date=10 December 2021|access-date=13 August 2021|url-status=live}}</ref><ref name="EMA extra doses">{{cite web|title=Comirnaty and Spikevax: EMA recommendations on extra doses and boosters|website=[[European Medicines Agency]] (EMA)|date=4 October 2021|url=https://www.ema.europa.eu/en/news/comirnaty-spikevax-ema-recommendations-extra-doses-boosters|archive-url=https://web.archive.org/web/20211211104957/https://www.ema.europa.eu/en/news/comirnaty-spikevax-ema-recommendations-extra-doses-boosters|archive-date=11 December 2021|access-date=4 October 2021|url-status=live}}</ref>

== منفي اغېزې ==
د واکسین د ازمېښتونو په درېیم لوی پړاو کې د هېڅ کومې جدي روغتیايي ستونزې راپور نه دی ورکړی شوی او مهم جانبي عوارض ډېر کم لیدل شوي دي.<ref name="herper3">{{cite web|vauthors=Herper M|title=Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate|url=https://www.statnews.com/2020/11/09/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate/|work=[[Stat (website)|Stat News]]|access-date=9 November 2020|date=9 November 2020|archive-date=9 November 2020|archive-url=https://web.archive.org/web/20201109114554/https://www.statnews.com/2020/11/09/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate/|url-status=live}}</ref><ref name=":42">{{cite press release|title=Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study|website=BioNTech|date=1 April 2021|url=https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-confirm-high-efficacy-and-no-serious-safety|access-date=11 April 2021|archive-date=4 April 2021|archive-url=https://web.archive.org/web/20210404130905/https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-confirm-high-efficacy-and-no-serious-safety|url-status=live}}</ref>

د کوویډ-۱۰ فایزر-بیو اېن‌ټېک واکسین جانبي عوارض خفیف او متوسط دي او په څو ورځو کې له منځه ځي. د لویانو د نورو واکسینونو جانبي عوارضو ته ورته دي او هغه طبیعي نښې دي چې بدن د ویروس په مقابل کې خوندیتوب رامنځته کوي. د کلینيکي ازمېښتونو په جریان کې هغه جانبي عوارض چې په هرو لسو کسانو کې تر یوه ډېر کسان اغېزمنوي دا دي: د تزریق په ځای کې درد، ستړیا، سر دردي، د بدن د غړیو درد، لړزه، د مفاصلو درد او تبه. تبه د دویم ډوز تر اخیستو وروسته ډېره معموله ده.<ref name=":72">{{Cite web|date=19 November 2021|title=Pfizer-BioNTech COVID-19 Vaccine (also known as Comirnaty) Overview and Safety|url=https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html|archive-url=https://web.archive.org/web/20211206135118/https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html|archive-date=6 December 2021|access-date=27 September 2021|website=U.S. [[Centers for Disease Control and Prevention]] (CDC)|url-status=live}}</ref><ref name="Comirnaty product information">{{cite report|url=https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf|title=Comirnaty: Product Information|access-date=23 December 2020|publisher=[[European Medicines Agency]] (EMA)|date=|archive-date=24 December 2020|archive-url=https://web.archive.org/web/20201224122112/https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf|url-status=live}}</ref>

د اروپا طبي مرکز (EMA) په منظم ډول د دغه واکسین د خوندیتابه اړوند اطلاعات څېړي. د خوندیتابه هغه راپور چې دغه مرکز د ۲۰۲۱ ز کال د سپټمبر میاشتې په ۸مه نېټه خپور کړی، په اروپايي اتحادیه کې د څه باندې ۳۹۲ میلیون ډوزونو پر بنسټ ولاړ دی. د اروپا طبي مرکز وايي چې "د دغه واکسین ښېګڼې د کوویډ-۱۹ په مخنیوي کې تر هر ډول خطر زیاتې دي او د کارولو لپاره یې په سپارښتنه کې هېڅ ډول بدلون نه‌شته." هغه کم جانبي عوارض (چې ښايي په هرو ۱۰۰۰ کسانو کې ۱ کس اغېزمن کړي) د مخ یوې خوا ته کږېدل او د مخ د پړسوب په څېر حساسیتي غبرګونونه دي.

=== حساسیت ===
د پوليتیلن ګلیکول (polyethylene glycol) پر وړاندې سخت حساسیت د کوویډ-۱۹ فایزر واکسین د استفادې د ممنوعیت په توګه یاد شوی دی. د تجویز شوي واکسین په هرو یو میلیون ډوزونو کې کابو ۱۱ سخت حساسیتونه لیدل شوي دي. د متحدو ایالتونو د ناروغیو د کنترول او مخنیوي مرکز د راپور له مخې ۷۱ سلنه دغه حساسیتونه د واکسین تر تطبیق ۱۵ دقیقې وروسته پېښ شوي او تر ډېره (۸۱ سلنه) په هغو اشخاصو کې لیدل شوي چې د حساسیت مخینه یې لرله. د بریتانیا د درملو او روغتیايي محصولاتو د تنظیم مرکز د ۲۰۲۰ ز کال د ډسمبر میاشتې په ۹مه نېټه سپارښتنه وکړه چې حساسیت ‌لرونکي اشخاص باید د کوویډ-۱۹ فایزر واکسین ونه‌کړي. د ډسمبر په ۱۲مه نېټه د کاناډا د تنظیم ادارې هم دې ته ورته اقدام وکړ او ویې ویل: "په بریتانیا کې دواړو اشخاصو د سخت حساسیت مخینه لرله چې د دواړو درملنه وشوه او روغ شول."<ref>{{cite journal|vauthors=Rutkowski K, Mirakian R, Till S, Rutkowski R, Wagner A|date=June 2021|title=Adverse reactions to COVID-19 vaccines: A practical approach|journal=Clinical and Experimental Allergy|volume=51|issue=6|pages=770–777|doi=10.1111/cea.13880|pmc=8250847|pmid=33813758}}</ref><ref name=":1">{{cite journal|date=January 2021|title=Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020|url=https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7002e1-H.pdf|journal=MMWR. Morbidity and Mortality Weekly Report|volume=70|issue=2|pages=46–51|doi=10.15585/mmwr.mm7002e1|pmc=7808711|pmid=33444297|doi-access=free|url-status=live|author1=CDC COVID-19 Response Team}}</ref><ref name="EU safety update">{{cite web|date=28 January 2021|title=COVID-19 vaccine safety update: Comirnaty|url=https://www.ema.europa.eu/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-january-2021_en.pdf|archive-url=https://web.archive.org/web/20210602213346/https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-28-january-2021_en.pdf|archive-date=2 June 2021|access-date=30 January 2021|publisher=[[European Medicines Agency]] (EMA)|url-status=live}}</ref><ref name="mhra-allergy">{{cite web|date=9 December 2020|title=MHRA warning after allergic reactions in NHS staff given COVID-19 vaccine|url=https://www.gponline.com/mhra-warning-allergic-reactions-nhs-staff-given-covid-19-vaccine/article/1702322|archive-url=https://web.archive.org/web/20201209163321/https://www.gponline.com/mhra-warning-allergic-reactions-nhs-staff-given-covid-19-vaccine/article/1702322|archive-date=9 December 2020|access-date=9 December 2020|publisher=GP|vauthors=Bostock N|url-status=live}}</ref><ref name="WP-20201209">{{cite news|date=9 December 2020|title=Britain warns against Pfizer vaccine for people with history of 'significant' allergic reactions|newspaper=[[The Washington Post]]|url=https://www.washingtonpost.com/world/pfizer-allergic-warnings-vaccine/2020/12/09/4e79ec72-3a16-11eb-aad9-8959227280c4_story.html|access-date=9 December 2020|archive-url=https://web.archive.org/web/20201209195847/https://www.washingtonpost.com/world/pfizer-allergic-warnings-vaccine/2020/12/09/4e79ec72-3a16-11eb-aad9-8959227280c4_story.html|archive-date=9 December 2020|vauthors=Booth W, Cunningham E|url-status=live}}</ref><ref name="cekdis20">{{cite journal|vauthors=Cabanillas B, Akdis CA, Novak N|date=June 2021|title=Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?|journal=Allergy|volume=76|issue=6|pages=1617–1618|doi=10.1111/all.14711|pmid=33320974|doi-access=free|s2cid=229284320|title-link=doi}}</ref><ref name="hc12dec">{{cite web|date=12 December 2020|title=Pfizer–BioNTech COVID-19 vaccine: Health Canada recommendations for people with serious allergies|url=https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/74543a-eng.php|archive-url=https://web.archive.org/web/20201222224308/https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/74543a-eng.php|archive-date=22 December 2020|access-date=21 December 2020|publisher=[[Health Canada]]|url-status=live}}</ref>

=== د زړه د عضلاتو پړسوب ===
د ۲۰۲۱ کال په جون میاشت کې د اسرائیلو د روغتیا وزارت وویل چې:  په ځینو ۱۶ تر ۳۰ کلنو نرانو کې احتمالاً د دغه واکسین دویم ډوز د زړه د عضلاتو پړسوب (myocarditis) رامنځته کولی شي. د ۲۰۲۰ز کال د ډسمبر او د ۲۰۲۱ ز کال د مې میاشتو تر منځ د هر یو میلیون واکسین شویو کسانو له ډلې په ۵۵ کسانو کې د زړه د عضلاتو د التهاب پېښې ثبت شوې وې چې ۹۵ سلنه یې خفیفې وبلل شوې. د ۲۰۲۱ ز کال له اپرېل میاشتې راهیسې په متحدو ایالتونو کې د زړه د عضلاتو د الهتاب (myocarditis) او د زړه د عضلاتو د خارجي پړسوب (pericarditis) پېښې ثبت شوې دي چې په هر یو میلیون ځوانانو کې شاوخوا ۱۳ کسان دي، تر ډېره نارینه دي او عمرونه یې له ۱۶ کلونو پورته دي چې د فایزر واکسین تر تطبیق وروسته یې پېښې ثبت شوې دي. په دې کې ډېری ناروغ کسان د درملنې او کافي استراحت په مرسته ډېر ژر بېرته رغېدلي دي.<ref name=":8">{{cite news|date=2 June 2021|title=Israel sees probable link between Pfizer vaccine and myocarditis cases|work=Reuters|url=https://www.reuters.com/world/middle-east/israel-sees-probable-link-between-pfizer-vaccine-small-number-myocarditis-cases-2021-06-01/|access-date=3 June 2021|archive-url=https://web.archive.org/web/20210625045743/https://www.reuters.com/world/middle-east/israel-sees-probable-link-between-pfizer-vaccine-small-number-myocarditis-cases-2021-06-01/|archive-date=25 June 2021|vauthors=Heller J|url-status=live}}</ref><ref>{{cite web|author=National Center for Immunization and Respiratory Diseases|title=Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination|url=https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html|website=U.S. [[Centers for Disease Control and Prevention]] (CDC)|access-date=2 July 2021|date=23 June 2021|archive-date=3 July 2021|archive-url=https://web.archive.org/web/20210703101038/https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html|url-status=live}}</ref><ref>{{cite web|title=Clinical Considerations: Myocarditis after mRNA COVID-19 Vaccines|website=U.S. [[Centers for Disease Control and Prevention]] (CDC)|url=https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html|access-date=27 June 2021|archive-date=27 June 2021|archive-url=https://web.archive.org/web/20210627075945/https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html|url-status=live}} {{PD-notice}}</ref><ref name="biontech">{{Cite journal|vauthors=Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, Edwards K, Soslow JH, Dendy JM, Schlaudecker E, Lang SM, Barnett ED, Ruberg FL, Smith MJ, Campbell MJ, Lopes RD, Sperling LS, Baumblatt JA, Thompson DL, Marquez PL, Strid P, Woo J, Pugsley R, Reagan-Steiner S, DeStefano F, Shimabukuro TT|display-authors=6|date=January 2022|title=Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021|journal=JAMA|volume=327|issue=4|pages=331–340|doi=10.1001/jama.2021.24110|pmid=35076665|doi-access=free|title-link=doi|pmc=8790664|pmc-embargo-date=July 25, 2022}}</ref>

== سرچينې ==
